SUFU 23 Panel: Beta-3 Agonists in the Treatment of Overactive Bladder
Update: 2023-12-20
Description
Moderator: J. Quentin Clemens, MD, FACS
Risk Profile of Anticholinergic Agents vs Beta-3 Agonists
Panelist: Anne M. Suskind, MD, MS, FACS, FPMRS
Efficacy of Anticholinergic Agents vs Beta-3 Agonists
Panelist: Blayne Welk, MD
What About Neurogenic Bladder?
Panelist: Christopher S. Elliott, MD, PhD
Comments
In Channel